| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| ln Vitro |
UNC9426 (compound 12) (0.5 nM-10 μM) showed different binding efficiencies to three members of the TAM kinase family (TYRO3, MERTK and AXL), with the highest affinity for TYRO3 (EC50 = 89.8 nM) [1]. UNC9426 (10 μM, 10 min) inhibited human platelet aggregation and reduced the expression of human platelet surface activation markers PAC-1 and P-selectin [1]. UNC9426 (100-10000 nM, 0-10 h) significantly inhibited the phagocytic activity of macrophages in THP1 cells [1]. UNC9426 (30-10000 nM, 7-10 days) showed strong inhibitory effects on colony formation in NSCLC cell cultures, with EC50 values of 170 nM (H1650) and 197 nM (H1975), respectively [1].
|
|---|---|
| ln Vivo |
UNC9426 (10 mg/kg, intravenous injection) did not cause significant bleeding side effects in C57BL/6 mice [1].
|
| Animal Protocol |
Animal/Disease Models:Wild-type C57BL/6 mice (6-12 weeks old) [1]
Doses: 10 mg/kg Route of Administration:Intravenous injection Experimental Results:Compared with the control group, this study shortened the total bleeding time and the time to first hemostasis in mice. During the 15-minute experimental period, this study did not significantly affect the number of rebleeding episodes in mice. |
| References |
| Molecular Formula |
C32H34F6N6O
|
|---|---|
| Molecular Weight |
632.64
|
| CAS # |
3051784-94-9
|
| Appearance |
White to off-white solid
|
| SMILES |
O[C@H](CC1)CC[C@@H]1N2C=C(C3=CC=C(C=C3)CN4CCN(CC4)C)C5=CN=C(N=C52)NC6=CC(C(F)(F)F)=CC(C(F)(F)F)=C6
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~20.59 mg/mL (~32.55 mM; ultrasonic and warming and heat to 60°C)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5807 mL | 7.9034 mL | 15.8068 mL | |
| 5 mM | 0.3161 mL | 1.5807 mL | 3.1614 mL | |
| 10 mM | 0.1581 mL | 0.7903 mL | 1.5807 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
